Chris Peetz

Role: Chief Executive Officer at Mirum Pharmaceuticals, Inc.
Location: San Francisco, CA, US
LinkedIn followers: 500 followers

General Business & ManagementView LinkedIn profile

Experience

Chief Executive Officer
Mirum Pharmaceuticals, Inc.
Mar 2019 — Present

Skills

Competitive Intelligence
Due Diligence
Competitive Analysis
Biotechnology
Product Development
Analytics
Business Development
Strategy
Drug Development
Entrepreneurship
Financial Modeling
Product Marketing
Finance
Regulatory Affairs
Powerpoint
Global Marketing
Drug Discovery
Strategic Planning
Fda
Strategic Partnerships
Immunology
Valuation
Product Management
Lifesciences
Market Analysis
Mergers & Acquisitions
Technology Transfer
Market Research
Cancer
Clinical Development
Product Launch
Licensing
Infectious Diseases
Cross-Functional Team Leadership
Business Strategy
Clinical Trials
Corporate Development
Biopharmaceuticals
Medical Devices
Intellectual Property

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
c••••••••@mirumpharma.com
Personal email
•••••@•••••.com
Direct dial
+16•••••••33

Unlock verified contacts

Free to start · No credit card required

Current company

Mirum Pharmaceuticals, Inc.

Pharmaceutical Manufacturing · 496 employees · Founded 2018 · Foster City, California, United States

Mirum Pharmaceuticals is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com.

mirumpharma.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Experience

Chief Executive Officer

Skills

Find verified contacts for anyone on LinkedIn